June 8th 2021
Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.
March 27th 2021
Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
February 9th 2020
Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.